Skip to main content
Download PDF

The 95% effective dose of dexmedetomidine to induce adequate sedation in patients with chronic insomnia disorder: a biased coin design up-and-down sequential allocation trial

BMC Anesthesiology volume 24, Article number: 368 (2024) Cite this article

Abstract

Background

Chronic insomnia disorder is a common sleep disorder. Previous studies have reported increased demand for anesthetics in patients with chronic insomnia disorder. However, few studies have investigated the effective dose of dexmedetomidine for sedation in patients with chronic insomnia disorder. We aimed to determine the 95% effective dose of dexmedetomidine to induce adequate sedation in patients with chronic insomnia disorder.

Methods

This is a biased coin design up-and-down sequential allocation trial in patients aged 18–65 years with chronic insomnia disorder (n = 60). The dose of dexmedetomidine for the subsequent patient was determined based on the response of the previous patient, with an interval of 0.1 µg/kg. Sedation was assessed using the bispectral index. The 95% effective dose was calculated using isotonic regression.

Results

The 95% effective dose of dexmedetomidine to induce adequate sedation in patients with chronic insomnia disorder was 1.75 (95% confidence interval, 1.70–1.94) µg/kg. Four patients (6.7%) experienced bradycardia and no other adverse events were observed during the study.

Conclusions

The 95% effective dose of dexmedetomidine to induce adequate sedation in patients with chronic insomnia disorder was 1.75 µg/kg.

Trials registration

Chinese Clinical Trial Registry (ChiCTR2200063212); first registered 01/09 /2022.

Peer Review reports

Background

Insomnia disorder is one of the most common sleep disorders, characterized by difficulty falling asleep, difficulty maintaining sleep, and/or waking up earlier than intended, in addition to daytime functional impairment [1, 2]. Chronic insomnia disorder (CID) is defined by the presence of clinical symptoms of insomnia disorder for at least three nights a week that last for at least 3 months [3]. The pathological process of CID includes increased cortical activity, increased sympathetic excitability, and excessive arousal [4,5,6]. Additionally, the prevalence of anxiety disorder in patients with insomnia disorder is 20–30% [7]. Several clinical studies have reported increased demand for anesthetics in patients with insomnia or anxiety disorder [8,9,10].

Dexmedetomidine, a selective α2-adrenergic receptor agonist, has been widely used to induce perioperative sedation and analgesia [11]. Dexmedetomidine is anticipated to be a new type of sleep enhancer to treat the symptoms of insomnia since it can approximate physiological sleep with fewer adverse events [12]. However, the effective dose of intravenous dexmedetomidine for sedation in patients with CID has not yet been adequately described in the literature.

This study aimed to determine the 95% effective dose (ED95) of dexmedetomidine to induce adequate sedation in patients with CID using the biased coin design up-and-down sequential method (BCD-UDM).

Methods

The Institutional Review Board of Shanghai Fourth People’s Hospital, Shanghai, China approved this study on 27 July 2022 (File No. 2022003-001; Chairperson, Hui Chen). Written informed consent was obtained from all patients. This study was registered on the Chinese Clinical Trial Registry (ChiCTR2200063212) on 01/09/2022. The research was conducted at Shanghai Fourth People’s Hospital, Shanghai, China between 1 September 2022, and 12 November 2023.

Patients were recruited from the outpatient sleep medicine clinics of Shanghai Fourth People’s Hospital. The criteria for inclusion were as follows: age, 18–65 years; fulfillment of the diagnostic criteria for CID per the third edition of the international classification of sleep disorders; subjective sleep onset latency > 30 min. The criteria for exclusion were as follows: lack of consent; the presence of bradycardia, hypotension, liver and kidney dysfunction; use of occupational sleep apnea solutions; restless legs syndrome; pregnancy or breastfeeding; shift work or irregular bedtime; untreated anxiety, depression or other mental disorders; allergy to dexmedetomidine.

Sedation protocol

All patients who volunteered to participate in the experiment were included. We asked the patients to fast for 4 h considering that they did not need to undergo surgery or an invasive exam. The patients were given the dexmedetomidine by an anesthetist in a monitored area. After measuring non-invasive blood pressure, heart rate (HR), and pulse oxygen saturation (SpO2) by BeneView T6 monitoring system (Mindray Medical International Co., Ltd, Guangdong, China), intravenous access was established. Bispectral index (BIS) monitoring (Aspect Medical Systems, Inc., MA, USA) was performed on all patients to evaluate the depth of sedation in this study.

Before administration, 10 µg/ml dexmedetomidine was prepared by diluting 200 µg dexmedetomidine (2 ml) (Youbituo™; Yangtze River Pharmaceutical Group Co., Ltd, China; 200 µg/ml) in saline 0.9% (18 ml). After being further diluted in saline 0.9% to 20 ml, the study dose was administered intravenously using an infusion pump (Mindray Medical International Co., Ltd, Guangdong, China). The infusion rate was 120 mL/h and the infusion time was 10 min.

Successful sedation was defined as BIS < 60 within 40 min following the initial dexmedetomidine administration. Failed sedation was defined as BIS ≥ 60 within 40 min following the initial dexmedetomidine administration. Sedation onset time was defined as the duration between the initial dexmedetomidine administration and BIS < 60. Adequate sedation time was defined as the time from sedation onset to BIS ≥ 60. Sedation time was defined as the time from sedation onset to BIS ≥ 90.

The mean arterial pressure (MAP), HR, SpO2 and BIS were collected at baseline and continuously monitored. The BIS recorded every 1 min until BIS ≥ 90. The MAP, HR and SpO2 recorded every 5 min until the patients were transported from the monitored area to the general ward. A Modified Aldrete score of 9 or higher was required to be transported to the general ward [13]. Given that residual dexmedetomidine may increase the risk of falls, particularly in patients taking hypnotic medications, all patients were admitted for one night of observation. The following morning, the patients were assessed in the general ward to document any adverse events such as nausea, vomiting and falls, through self-reporting.

Six milligrams of ephedrine and 0.5 mg of atropine were immediately accessible for every patient as rescue medications. Ephedrine or atropine was used to treat hypotension or bradycardia, and these boluses could be repeated as needed. Hypoxia was treated with oxygen inhalation through a nasal cannula or simple mask. Hypotension was defined as the MAP < 60 mmHg. Bradycardia was defined as HR < 50 beats per minute. Hypoxia was defined as SpO2 < 90%.

Biased coin design up-and-down sequential method

We used the BCD-UDM to determine the ED95 of dexmedetomidine for the sedation of patients with CID. The starting dose of dexmedetomidine in this study was set at 0.8 µg/kg. The dose for each of the subsequent patients was determined based on the response of the previous patient. In case of a failed sedation, the dose was increased for the following patient by 0.1 µg/kg. While in the case of a successful sedation, the following patient was randomly chosen to either receive the same dose at P = 0.95 or a dose decreased by 0.1 µg/kg at P = 0.05. The biased coin allocation was achieved by a list of random responses, which was prepared by a statistician with Excel 2021. A research assistant used this random list to provide the dose of dexmedetomidine for the subsequent patient and set the delivery system. The anesthesiologists and patients remained blinded to the dose of dexmedetomidine throughout the study.

Outcome measurements

The primary outcome of the study was determining the ED95 of dexmedetomidine to induce adequate sedation in patients with CID. The secondary outcomes included BIS values, sedation onset time, adequate sedation time, sedation time, and the incidence of bradycardia, hypotension, hypoxia, nausea, vomiting, and falls.

Statistical methods

Owing to the non-independence of the assignment of doses and the unknown distribution, the precise sample size for the BCD-UDM could not be determined [14]. A minimum sample size of 45 successful subjects is required for the BCD-UDM [15]. Owing to a lack of references, determining the appropriate starting dose of dexmedetomidine was challenging. Inappropriate starting doses may result in the need for more samples in BCD-UDM [15]. Taking into account these reasons, this study involved 60 patients with CID.

The ED95 was calculated using isotonic regression analysis, and the 95% confidence interval (CI) was generated from 2,000 bootstrapped samples [16]. An adjusted response probability was obtained using the pooled-adjacent-violators algorithm (PAVA) [16]. R for Windows version 4.2.2 was used to perform the statistical analysis.

Categorical variables were presented as frequency. The normality of continuous variables was assessed using the Shapiro − Wilk test. Normally distributed data were presented as the mean ± standard deviation, and non-normally distributed data were presented as the median (interquartile range). BIS variables were analyzed by one-way repeated-measures analysis of variance. We used SPSS 26.0 for Windows as the statistical software.

Results

Eighty-two patients with CID were evaluated for inclusion in this study between 25 September 2023, and 9 November 2023. Among them, 16 patients did not meet the inclusion criteria and 6 patients refused to participate. Finally, 60 patients were included, all of whom completed the study (Fig. 1); among them, 48 and 12 patients demonstrated successful and failed sedation, respectively.

Fig. 1
figure 1

Flow diagram depicting patient inclusion and exclusion criteria in the study

Full size image

The patient characteristics, time of sedation onset, and sedation period are demonstrated in Table 1. The onset time was 13.6 ± 4.9 min, the adequate sedation time was 18.5 ± 7.6 min, and the sedation time was 34.1 ± 9.5 min.

Table 1 Characteristics of patients who received dexmedetomidine sedation
Full size table

The sequence of patients and the response of each patient to the assigned dose are illustrated in Fig. 2. The ED95 value of dexmedetomidine calculated using isotonic regression analysis was 1.75 (95% CI, 1.70–1.94) µg/kg for the sedation of patients with CID. The frequency of response to the assigned dexmedetomidine dose and the observed and PAVA-adjusted success rates are demonstrated in Table 2.

Fig. 2
figure 2

Process for determining the ED95 of dexmedetomidine to induce adequate sedation of patients with chronic insomnia disorder. Successful doses are denoted by solid circles, failed doses are denoted by open circles. The horizontal line represents the ED95; error bars represent the 95% confidence interval. ED95, 95% effective dose. * The patients who experienced bradycardia

Full size image
Table 2 Observed and pooled-adjacent-violators algorithm (PAVA)-adjusted success rates
Full size table

Following the initial dexmedetomidine administration, a significant decline was observed in BIS from the baseline at 5 min; it reached the lowest level at 20 min and returned to baseline at 65 min (Fig. 3).

Fig. 3
figure 3

BIS response to dexmedetomidine administration. Significant decrease in BIS from baseline was observed at 5 min after initial dexmedetomidine administration; it reached the lowest level at 20 min and returned to baseline at 65 min. *P < 0.001 compared to baseline. BIS, bispectral index

Full size image

Four patients (6.7%) experienced bradycardia and recovered after receiving 0.5 mg atropine (Fig. 2). No other adverse events including hypotension, hypoxia, nausea, vomiting or falls were observed in this study.

Discussion

Our study demonstrated that the ED95 of dexmedetomidine to induce adequate sedation in patients with CID was 1.75 (95% CI, 1.70–1.94) µg/kg. In this study, four patients (6.7%) experienced bradycardia and no other adverse were events observed.

Insomnia disorder is the most common sleep disorder affecting 6–10% of the general population [17]. In addition, it is estimated that 260–360 million surgeries are performed annually worldwide [18]. Previous studies have demonstrated that intraoperative dexmedetomidine use can improve postoperative sleep quality in patients undergoing surgery [19, 20]. It can be inferred that a large number of patients with CID require perioperative sedation each year. Therefore, it is necessary to determine the effective dose of dexmedetomidine for sedation in patients with CID. To our knowledge, this was the first study to investigate the effective dose of dexmedetomidine to induce sedation in patients with CID, which could provide clinical guidance.

Previous studies have investigated the 50% effective doses (ED50) of dexmedetomidine using the conventional up-and-down sequential method (UDM) [21, 22]. However, ED50 has limited clinical significance since it indicates a 50% failure rate by definition. Unlike ED50, ED95 indicates the dose of drug required to produce effects in most patients. In clinical practice, knowing the ED95 helps anaesthetists determine the anaesthetic dose needed to ensure most patients achieve adequate anaesthesia to prevent movement or pain during surgery. The conventional UDM extrapolates ED95 from ED50, which cannot be verified, whereas BCD-UDM can directly estimate ED95 [15]. In many UDM studies, parameter estimators (logistic or probit regression) were used to calculate the CI of potency doses [23]. However, it has been demonstrated that the parameter estimators underestimate the statistical variation in potency doses, leading to an unreasonably narrow CI [24]. The isotonic regression technique obtains adjusted response probabilities using PAVA, estimates ED95 using nonparametric isotonic regression, and calculates CI using a parametric bootstrap routine. These methods reduce bias by relying less on untestable hypotheses [15]. In this study, we used BCD-UDM and isotonic regression analysis to estimate the ED95 of dexmedetomidine for the sedation of patients with CID, which can reduce bias and variance.

We selected BIS to asses sedation levels since recoding some subjective scores, such as observer’s assessment of alert/sedation (OAA/S) and Ramsay sedation scores, requires the repeated stimulation of patients, which results in an uncomfortable experience, especially in patients with CID. According to previous studies, there is a significant correlation between BIS and subjective scores during dexmedetomidine sedation [25,26,27]. Since 85% of the BIS values were between 40 and 60 when the OAA/S responsiveness was 3 during dexmedetomidine sedation [26], we defined successful sedation as BIS < 60 after dexmedetomidine administration in this study.

Intravenous dexmedetomidine may cause hypotension and bradycardia due to its central sympatholytic effects [28]. For procedural sedation, a loading dose of dexmedetomidine of 1 µg/kg followed by a maintenance infusion beginning at 0.6 µg/kg/h is recommended [29]. Candiotti et al. and Bergese et al. demonstrated that the incidence of hypotension and bradycardia in procedural sedation with dexmedetomidine was 8.5–27.3% and 4.7–7.3%, respectively. In this study, 56 patients (93.3%) received a loading dose of dexmedetomidine higher than 1 µg/kg; however, no patient experienced hypotension only four patients (6.7%) experienced bradycardia. Our study revealed that dexmedetomidine can induce adequate sedation in patients with CID safely. We speculate that the increased sympathetic excitability associated with insomnia may play a role in modulating patients with CID tolerance to the cardiovascular effects of dexmedetomidine.

Xiong et al. demonstrated that the ED95 of a single bolus of dexmedetomidine for adequate sedation (OAA/S ≤ 3) was 1.80 µg/kg in parturients and 1.10 µg/kg in non-pregnant females, respectively [30]. Kim et al. revealed that the ED95 for light sedation (OAA/S 3/4) was 0.57 µg/kg in patients aged 45 − 64 years undergoing spinal anesthesia for transurethral prostate excision [31]. Our study revealed that 1.75 µg/kg dexmedetomidine can induce adequate sedation (BIS < 60) in patients with CID. Owing to the different definitions of successful sedation, we could not determine that patients with CID require a higher dose of dexmedetomidine than the general population to achieve the same level of sedation; thus, further controlled trials are necessary to establish this.

Dexmedetomidine decreases rapid eye movement (RME) sleep and increases non-REM stage 2 (NREM2) sleep in patients without CID, and an increased dose of dexmedetomidine can induce non-REM stage 3 (NREM3) sleep when deep sedation is achieved [32, 33]. A preliminary study has explored the feasibility of using dexmedetomidine in the treatment of CID albeit they did not use polysomnography to compare sleep reported and did not determine the sleep-inducing dose of dexmedetomidine [34]. The ability and dose of dexmedetomidine to induce NREM2 or NREM3 sleep in patients with CID must be further explored.

This study has some limitations that should be considered. First, the design of this study was uncontrolled, limiting the conclusions that could be drawn and not determining without doubts that patients with CID have a higher demand for dexmedetomidine. We could not determine that patients with CID have a higher demand for dexmedetomidine. Second, the study is that we only enrolled patients aged 18–65 years and not older patients. Elderly patients are more susceptible to hypotension and bradycardia following the administration of dexmedetomidine than are younger patients owing to the drug’s decreased clearance rate and prolonged half-life [35, 36]. Dexmedetomidine is therefore prescribed at a lower dose for elderly patients. Third, patients with untreated anxiety, depression or other mental disorders were excluded, which impacts the clinical interpretation. Future studies should include recruiting patients with co-medications and co-morbidities. Fourth, patients with CID usually take sedative drugs, such as benzodiazepines, tricyclic antidepressants, histamine receptor antagonists, and antipsychotics [37, 38], which might influence the degree of sedation. Fifth, this study did not assess and grade patients based on CID severity.

Conclusion

In conclusion, this study demonstrated that the ED95 of dexmedetomidine to induce adequate sedation in patients with CID who met the study criteria was 1.75 µg/kg.

Data availability

The datasets of this study are available from the corresponding author on reasonable request.

Abbreviations

CID:

Chronic insomnia disorder

ED95:

95% effective dose

BCD-UDM:

Biased coin design up-and-down sequential method

HR:

Heart rate

SpO2:

Pulse oxygen saturation

BIS:

Bispectral index

MAP:

Mean arterial pressure

CI:

Confidence interval

PAVA:

Pooled-adjacent-violators algorithm

ED50:

50% effective doses

UDM:

Up-and-down sequential method

OAA/S:

Observer’s assessment of alert/sedation

RME:

Rapid eye movement

NREM2:

Non-rapid eye movement stage 2

NREM3:

Non-rapid eye movement stage 3

References

  1. Ohayon MM, Reynolds CF. Epidemiological and clinical relevance of insomnia diagnosis algorithms according to the DSM-IV and the International classification of Sleep disorders (ICSD). Sleep Med. 2009;10:952–60.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Morin CM, Benca R. Chronic insomnia. Lancet. 2012;379:1129–41.

    Article  PubMed  Google Scholar 

  3. Blake MJ, Trinder JA, Allen NB. Mechanisms underlying the association between insomnia, anxiety, and depression in adolescence: implications for behavioral sleep interventions. Clin Psychol Rev. 2018;63:25–40.

    Article  PubMed  Google Scholar 

  4. Pigeon WR, Cribbet MR. The pathophysiology of insomnia: from models to molecules (and back). Curr Opin Pulm Med. 2012;18:546–53.

    Article  PubMed  CAS  Google Scholar 

  5. Riemann D, Nissen C, Palagini L, Otte A, Perlis ML, Spiegelhalder K. The neurobiology, investigation, and treatment of chronic insomnia. Lancet Neurol. 2015;14:547–58.

    Article  PubMed  Google Scholar 

  6. Levenson JC, Kay DB, Buysse DJ. The pathophysiology of insomnia. Chest. 2015;147:1179–92.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Ohayon MM. Observation of the natural evolution of Insomnia in the American General Population Cohort. Sleep Med Clin. 2009;4:87–92.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hong JY, Kang IS, Koong MK, Yoon HJ, Jee YS, Park JW, et al. Preoperative anxiety and propofol requirement in conscious sedation for ovum retrieval. J Korean Med Sci. 2003;18:863–8.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Osborn TM, Sandler NA. The effects of preoperative anxiety on intravenous sedation. Anesth Prog. 2004;51:46–51.

    PubMed  PubMed Central  Google Scholar 

  10. Erden V, Abitağaoğlu S, Güler C, Doğan Z, Kırgezen Ş, Abut Y. Insomnia may increase anesthetic requirement. J Clin Anesth. 201;34:367–72.

  11. Giovannitti JA, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62:31–9.

    Article  PubMed  Google Scholar 

  12. Akeju O, Hobbs LE, Gao L, Burns SM, Pavone KJ, Plummer GS, et al. Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans:a pilot study. Clin Neurophysiol. 2018;129:69–78.

    Article  PubMed  Google Scholar 

  13. Aldrete JA, Kroulik D. A postanesthetic recovery score. Anesth Analg. 1970;49:924–34.

    Article  PubMed  CAS  Google Scholar 

  14. Wu B, Shan J, Zhou Q, Wang L. Determination of the ED95 of a single bolus dose of dexmedetomidine for adequate sedation in obese or nonobese children and adolescents. Brit J Anaesth. 2021;126:684–91.

    Article  PubMed  CAS  Google Scholar 

  15. Pace NL, Stylianou MP. Advances in and limitations of up-and-down methodology: a precis of clinical use, study design, and dose estimation in anesthesia research. Anesthesiology. 2007;107:144–52.

    Article  PubMed  Google Scholar 

  16. Stylianou M, Flournoy N. Dose finding using the biased coin up- and-down design and isotonic regression. Biometrics. 2002;58:171–7.

    Article  PubMed  Google Scholar 

  17. Morin CM, Jarrin DC. Epidemiology of Insomnia: prevalence, course, risk factors, and Public Health Burden. Sleep Med Clin. 2022;17:173–91.

    Article  PubMed  Google Scholar 

  18. Weiser TG, Haynes AB, Molina G, Lipsitz SR, Esquivel MM, Uribe-Leitz T, et al. Size and distribution of the global volume of surgery in 2012. B World Health Organ. 2016;94:201–F209.

    Article  Google Scholar 

  19. Duan G, Wang K, Peng T, Wu Z, Li H. The effects of Intraoperative Dexmedetomidine Use and its different dose on postoperative sleep disturbance in patients who have undergone non-cardiac major surgery: a real-world cohort study. Nat Sci Sleep. 2020;12:209–19.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chen Z, Tang R, Zhang R, Jiang Y, Liu Y. Effects of dexmedetomidine administered for postoperative analgesia on sleep quality in patients undergoing abdominal hysterectomy. J Clin Anesth. 2016;36:118–22.

    Article  PubMed  Google Scholar 

  21. Wang J, Han Z, Zhou H, Wang N, Ma H. Effective loading dose of Dexmedetomidine to induce adequate sedation in parturients undergoing caesarean section under spinal anaesthesia. Turk J Anaesthesiol Reanim. 2017;45:260–3.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  22. Xu B, Li Z, Zhou D, Li L, Li P, Huang H. The influence of age on sensitivity to dexmedetomidine sedation during spinal anesthesia in lower limb orthopedic surgery. Anesth Analg. 2017;125:1907–10.

    Article  PubMed  CAS  Google Scholar 

  23. Görges M, Zhou G, Brant R, Ansermino JM. Sequential allocation trial design in anesthesia: an introduction to methods, modeling, and clinical applications. Pediart Anesth. 2017;27:240–7.

    Article  Google Scholar 

  24. Vågerö M, Sundberg R. The distribution of the maximum likelihood estimator in up-and-down experiments for quantal dose-response data. J Biopharm Stat. 1999;9:499–519.

    Article  PubMed  Google Scholar 

  25. Turkmen A, Altan A, Turgut N, Vatansever S, Gokkaya S. The correlation between the Richmond agitation-sedation scale and bispectral index during dexmedetomidine sedation. Eur J Anaesth. 2006;23:300–4.

    Article  CAS  Google Scholar 

  26. Kasuya Y, Govinda R, Rauch S, Mascha EJ, Sessler DI, Turan A. The correlation between bispectral index and observational sedation scale in volunteers sedated with dexmedetomidine and propofol. Anesth Analg. 2009;109:1811–5.

    Article  PubMed  Google Scholar 

  27. Ki S, Lee D, Lee W, Cho K, Han Y, Lee J. Verification of the performance of the Bispectral Index as a hypnotic depth indicator during dexmedetomidine sedation. Anesth Pain Med (Seoul). 2022;17:44–51.

    Article  PubMed  Google Scholar 

  28. xDemiri M, Antunes T, Fletcher D, Martinez V. Perioperative adverse events attributed to α2-adrenoceptor agonists in patients not at risk of cardiovascular events: systematic review and meta-analysis. Brit J Anaesth. 2019;123:795–807.

    Article  Google Scholar 

  29. Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P. Clinical pharmacokinetics and pharmacodynamics of Dexmedetomidine. Clin Pharmacokinet. 2017;56:893–913.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  30. Xiong M, Chen B, Hu Z, et al. Dose comparison of Dexmedetomidine Sedation following spinal anesthesia: parturient versus Nonpregnant Women-A Randomized Trial. Anesthesiol Res Prac. 2020;2020:1059807.

    Google Scholar 

  31. Kim J, Kim WO, Kim HB, Kil HK. Adequate sedation with single-dose dexmedetomidine in patients undergoing transurethral resection of the prostate with spinal anaesthesia: a dose-response study by age group. Bmc Anesthesiol. 2015;15:17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  32. Chamadia S, Hobbs L, Marota S, Ibala R, Hahm E, Gitlin J, et al. Oral dexmedetomidine promotes non-rapid Eye Movement Stage 2 sleep in humans. Anesthesiology. 2020;133:1234–43.

    Article  PubMed  CAS  Google Scholar 

  33. Ramaswamy SM, Weerink MAS, Struys MMRF, Nagaraj SB. Dexmedetomidine-induced deep sedation mimics non-rapid eye movement stage 3 sleep: large-scale validation using machine learning. Sleep. 2021;44:zsaa167.

    Article  PubMed  Google Scholar 

  34. An JX, Williams JP, Fang QW, Wang Y, Liu H, Shi L, et al. Feasibility of patient-controlled sleep with dexmedetomidine in treating chronic intractable insomnia. Nat Sci Sleep. 2020;12:1033–42.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Iirola T, Ihmsen H, Laitio R, Kentala E, Aantaa R, Kurvinen JP, et al. Population pharmacokinetics of dexmedetomidine during long-term sedation in intensive care patients. Brit J Anaesth. 2012;108:460–8.

    Article  PubMed  CAS  Google Scholar 

  36. Wang C, Zhang H, Fu Q. Effective dose of dexmedetomidine as an adjuvant sedative to peripheral nerve blockade in elderly patients. Acta Anaesthesiol Scand. 2018;62:848–56.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  37. Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in adults: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13:307–49.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Wichniak A, Wierzbicka A, Walecka M, Jernajczyk W. Effects of antidepressants on Sleep. Curr Psychiatry Rep. 2017;19:63.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

None.

Funding

This study was supported by grants from Shanghai Fourth People’s Hospital, School of Medicine, Tongji University (No.SY-XKZT-2022-1005).

Author information

Authors and Affiliations

  1. Department of Anesthesiology and Perioperative medicine, Shanghai Key Laboratory of Anesthesiology and Brain Functional Modulation, Clinical Research Center for Anesthesiology and Perioperative Medicine, Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital, School of Medicine, Tongji University, Shanghai, China

    Mengya Li, Guifeng Li, Qifang Li & Qing Cai

Authors
  1. Mengya Li
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Guifeng Li
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Qifang Li
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Qing Cai
    View author publications

    You can also search for this author inPubMed Google Scholar

Contributions

LMY contributed to design the study，collect the date and draft the manuscript. LGF contributed to interpret and analyze the data. LQF and CQ contributed to design and conduct the study, and revise the manuscript. All authors reviewed the manuscript.

Corresponding authors

Correspondence to Qifang Li or Qing Cai.

Ethics declarations

Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Shanghai Fourth People’s Hospital, Shanghai, China. (File No. 2022003-001). Written informed consent was obtained from all patients. All methods in this study were performed in accordance with the relevant guidelines and regulations.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Conflict of interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, M., Li, G., Li, Q. et al. The 95% effective dose of dexmedetomidine to induce adequate sedation in patients with chronic insomnia disorder: a biased coin design up-and-down sequential allocation trial. BMC Anesthesiol 24, 368 (2024). https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12871-024-02759-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doiorg.publicaciones.saludcastillayleon.es/10.1186/s12871-024-02759-4

Keywords

BMC Anesthesiology

ISSN: 1471-2253

Contact us